Report : Europe Pulmonary Arterial Hypertension Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Drugs [Endothelin Receptor Antagonists (ERAs), Prostacyclin and Prostacyclin Analogs, sGC Stimulators, and pde-5 Dipsticks], Type (Branded and Generics), Route of Administration (Oral, Intravenous/Subcutaneous, and Inhalational), and Distribution Channel (Hospital Pharmacies and Clinics, Online Pharmacies, and Retail Pharmacies)

At 5.4% CAGR, the Europe Pulmonary Arterial Hypertension Market is speculated to be worth US$ 2,683.07 million by 2028, says Business Market Insights

According to Business Market Insights’ research, the Europe pulmonary arterial hypertension market was valued at US$ 1,959.47 million in 2022 and is expected to reach US$ 2,683.07 million by 2028, registering a CAGR of 5.4% from 2022 to 2028. Availability of generics at affordable costs due to growing patent expiration and growing incidence of pulmonary arterial hypertension are the critical factors attributed to the Europe pulmonary arterial hypertension market expansion.

Patent expiry permits generic drugs to penetrate the market and diversify product offerings. Over the next seven–eight years till 2030, the patented products are expected to go off-patent. This would provide an enormous opportunity for generic formulation companies in the coming years. Many pharma companies are already working to develop the generic version of patented products, finds Care Ratings. After patent expiration, generic versions of drugs can become available. While consumers benefit from low prices, losing patent protection can expose pharmaceutical companies to growing competition. Thus, patent expiration is expected to open up an opportunity for generic drug manufacturers to enter a new market. Thus, the growing patent expiration will offer lucrative opportunities for the Europe pulmonary arterial hypertension market expansion in the future.  

On the contrary, side effects of drugs used for treatment of pulmonary arterial hypertension hurdles the growth of Europe pulmonary arterial hypertension market.

Based on drugs, the Europe pulmonary arterial hypertension market is segmented into endothelin receptor antagonists (eras), prostacyclin and prostacyclin analogs, sGC stimulators, and pde-5 dipsticks. The prostacyclin and prostacyclin analogs segment held 37.2% share of Europe pulmonary arterial hypertension market in 2022, amassing US$ 728.61 million. It is projected to garner US$ 1,046.61 million by 2028 to expand at 6.2% CAGR during 2022–2028.

Based on type, the Europe pulmonary arterial hypertension market is bifurcated into branded and generics. The branded segment held 67.6% share of Europe pulmonary arterial hypertension market in 2022, amassing US$ 1,324.34 million. It is projected to garner US$ 1,839.22 million by 2028 to expand at 5.6% CAGR during 2022–2028.  

Based on route of administration, the Europe pulmonary arterial hypertension market is segmented into oral, intravenous/ subcutaneous, and inhalational. The oral segment held 46.5% share of Europe pulmonary arterial hypertension market in 2022, amassing US$ 910.19 million. It is projected to garner US$ 1,289.36 million by 2028 to expand at 6.0% CAGR during 2022–2028.

Based on distribution channel, the Europe pulmonary arterial hypertension market is segmented into hospital pharmacies and clinics, online pharmacies, and retail pharmacies. The hospital pharmacies and clinics segment held 47.2% share of Europe pulmonary arterial hypertension market in 2022, amassing US$ 924.72 million. It is projected to garner US$ 1,313.93 million by 2028 to expand at 6.0% CAGR during 2022–2028.

Based on country, the Europe pulmonary arterial hypertension market has been categorized into the UK, Germany, France, Italy, Spain, and the Rest of Europe.  Our regional analysis states that the UK captured 27.7% share of Europe pulmonary arterial hypertension market in 2022. It was assessed at US$ 541.99 million in 2022 and is likely to hit US$ 751.26 million by 2028, exhibiting a CAGR of 5.6% during the forecast period.  

Key players profiles in  the Europe pulmonary arterial hypertension market report are Bayer AG; Gilead Sciences Inc; GSK Plc; Johnson & Johnson; Lupin Ltd; Novartis AG; Pfizer Inc; Teva Pharmaceutical Industries Ltd; and United Therapeutics Corp among others.

  • Dec-2022, Sandoz Inc. (Sandoz) and Mainbridge Health Partners LLC (Mainbridge) entered into collaboration with Liquidia Corporation. Liquidia will support the development of a new subcutaneous pump for the infusion of Treprostinil Injection, for which it has the exclusive rights to promote and commercialize with Sandoz.
  • May-2021, Sandoz Treprostinil Injection, a generic Remodulin, is available for subcutaneous administration to treat patients diagnosed with PAH. Both options for intravenous and subcutaneous administration of Sandoz generic Treprostinil Injection are available at the same specialty pharmacy that dispenses the brand name medicine and is commercialized with Liquidia Corporation through a collaboration agreement.

Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: sam@businessmarketinsights.com

Download Free PDF Brochure